STEAP1-targeted strategies in advanced prostate cancer: a review on therapeutic and diagnostic implications.

IF 5.8 2区医学 Q1 ONCOLOGY

Prostate Cancer and Prostatic Diseases Pub Date : 2025-10-23 DOI:10.1038/s41391-025-01038-8

Ja Yoon Heo, Minzhi Sheng, Daniel Khalaf, Hon S Leong, Urban Emmenegger

{"title":"STEAP1-targeted strategies in advanced prostate cancer: a review on therapeutic and diagnostic implications.","authors":"Ja Yoon Heo, Minzhi Sheng, Daniel Khalaf, Hon S Leong, Urban Emmenegger","doi":"10.1038/s41391-025-01038-8","DOIUrl":null,"url":null,"abstract":"Background/objectives: Six transmembrane epithelial antigen of prostate 1 (STEAP1), a cell surface protein, is highly expressed in prostate cancer and is known to be associated with disease progression and poor prognosis. Based on its specificity for prostate cancer, significant progress has been made over the past decade to capitalize on STEAP1 as a diagnostic and treatment target, and its potential future role in prostate cancer care is of considerable interest.Subjects/methods: This review evaluates the current and emerging strategies targeting STEAP1, integrating findings from preclinical studies and clinical trials.Results: This review discusses STEAP1-based diagnostics, including molecular imaging (89Zr-DFO-MSTP2109A) and liquid biopsy methods, as well as therapeutics, such as STEAP1 antibodies, antibody-drug conjugates (DSPT3086S, ADRX-0405, ABBV-969, and DXC008), chimeric antigen receptor T-cell therapy (STEAP1 CAR-T), bispecific T-cell engagers (Xaluritamig/AMG 509, BC261), and cancer vaccines.Conclusions: STEAP1 represents a promising diagnostic and therapeutic target in prostate cancer, and its potential role in shaping future management of the disease warrants continued investigation.","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.8000,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate Cancer and Prostatic Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41391-025-01038-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/objectives: Six transmembrane epithelial antigen of prostate 1 (STEAP1), a cell surface protein, is highly expressed in prostate cancer and is known to be associated with disease progression and poor prognosis. Based on its specificity for prostate cancer, significant progress has been made over the past decade to capitalize on STEAP1 as a diagnostic and treatment target, and its potential future role in prostate cancer care is of considerable interest.

Subjects/methods: This review evaluates the current and emerging strategies targeting STEAP1, integrating findings from preclinical studies and clinical trials.

Results: This review discusses STEAP1-based diagnostics, including molecular imaging (89Zr-DFO-MSTP2109A) and liquid biopsy methods, as well as therapeutics, such as STEAP1 antibodies, antibody-drug conjugates (DSPT3086S, ADRX-0405, ABBV-969, and DXC008), chimeric antigen receptor T-cell therapy (STEAP1 CAR-T), bispecific T-cell engagers (Xaluritamig/AMG 509, BC261), and cancer vaccines.

Conclusions: STEAP1 represents a promising diagnostic and therapeutic target in prostate cancer, and its potential role in shaping future management of the disease warrants continued investigation.

查看原文本刊更多论文

晚期前列腺癌中以steap1为靶点的治疗和诊断策略综述

背景/目的：前列腺1六跨膜上皮抗原（STEAP1）是一种细胞表面蛋白，在前列腺癌中高表达，已知与疾病进展和不良预后相关。基于其对前列腺癌的特异性，在过去十年中，利用STEAP1作为诊断和治疗靶点取得了重大进展，其在前列腺癌治疗中的潜在未来作用备受关注。研究对象/方法：本综述综合了临床前研究和临床试验的结果，评估了针对STEAP1的当前和新兴策略。结果：本综述讨论了基于STEAP1的诊断方法，包括分子成像（89zr - dpo - mstp2109a）和液体活检方法，以及治疗方法，如STEAP1抗体、抗体-药物偶联物（DSPT3086S、ADRX-0405、ABBV-969和DXC008）、嵌合抗原受体t细胞治疗（STEAP1 CAR-T）、双特异性t细胞接合物（Xaluritamig/AMG 509、BC261）和癌症疫苗。结论：STEAP1在前列腺癌的诊断和治疗中是一个很有前景的靶点，它在塑造未来疾病管理中的潜在作用值得继续研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Prostate Cancer and Prostatic Diseases 医学-泌尿学与肾脏学

CiteScore

10.00

自引率

6.20%

发文量

142

审稿时长

6-12 weeks

期刊介绍： Prostate Cancer and Prostatic Diseases covers all aspects of prostatic diseases, in particular prostate cancer, the subject of intensive basic and clinical research world-wide. The journal also reports on exciting new developments being made in diagnosis, surgery, radiotherapy, drug discovery and medical management. Prostate Cancer and Prostatic Diseases is of interest to surgeons, oncologists and clinicians treating patients and to those involved in research into diseases of the prostate. The journal covers the three main areas - prostate cancer, male LUTS and prostatitis. Prostate Cancer and Prostatic Diseases publishes original research articles, reviews, topical comment and critical appraisals of scientific meetings and the latest books. The journal also contains a calendar of forthcoming scientific meetings. The Editors and a distinguished Editorial Board ensure that submitted articles receive fast and efficient attention and are refereed to the highest possible scientific standard. A fast track system is available for topical articles of particular significance.